Biosyent (RX) investor relations material

Executive summary

• Q2 2026 revenue reached $19.87M, up 95% year-over-year, driven by the first full quarter of the Oral Health segment post-acquisition; H1 2026 revenue was $33.8M, up 60% year-over-year.

• EBITDA for Q2 2026 was $5.0M, up 80% year-over-year; net income after tax was $2.85M, up 41% year-over-year.

• Fully diluted EPS for Q2 2026 was $0.25, up 39% year-over-year; trailing 12-month adjusted EPS was $0.89.

• 64 consecutive profitable quarters reported.

• Strategic priorities include profitable growth, portfolio diversification, and long-term value creation.

Financial highlights

• Pharmaceutical sales in Q2 2026 were $11.1M, up 14% year-over-year; Oral Health segment contributed $8.2M in its first full quarter.

• Insecticides segment sales rose 32% year-over-year in Q2 2026, but were down 5% for H1 2026.

• Gross profit for Q2 2026 was $13.97M, up 96% year-over-year; H1 2026 gross profit was $24.14M, up 49% year-over-year.

• EBITDA margin for Q2 2026 was 25% (26% adjusted for one-time acquisition costs); H1 2026 margin was 26% (27% adjusted).

• Cash and short-term investments at June 30, 2026 were $8.94M, down 62% from December 31, 2025.

Outlook and guidance

• Continued investment in pharmaceutical and oral health platforms, with projects underway to expand revenue outside Canada.

• Expectation to launch Thyconvi, a new liquid oral levothyroxine, in Q1 2027.

• Anticipates portfolio evolution through ongoing acquisition and in-licensing activity.

• Balance sheet expected to return to pre-acquisition strength by end of next year.

• Management highlights a strong balance sheet and diversified portfolio, positioning for continued profitable growth despite economic and geopolitical uncertainties.